ClinicalTrials.gg

Program

Chickenpox Vaccine

Also written as “Varicella Vaccine”, “Investigational live attenuated varicella vaccine” and “Zoster Vaccine, Live”.

Its studies are mostly in Chickenpox · Herpes Zoster · Meningococcal Infections · Measles · Streptococcal Infections, led by 6 companies.

Furthest: phase 4, since Feb 7, 200743 company-led studies, 6 open or runningNext primary completion: Dec 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck210 open or runningphase 4since Feb 7, 2007Apr 22, 2005none ahead
Sinovac Biotech124 open or runningphase 4since Oct 14, 2021Nov 14, 2016Dec 2028phase 4 · NCT06484686
GlaxoSmithKline60 open or runningphase 3since Sep 13, 2005Sep 13, 2005none ahead
Sinopharm22 open or runningphase 3since Dec 20, 2022Dec 20, 2022none ahead
Changchun Changsheng Life Science and Technology10 open or runningphase 4since Oct 24, 2013Oct 24, 2013none ahead
GC Biopharma10 open or runningphase 3since Nov 28, 2017Nov 28, 2017none ahead

Also a collaborator on its studies: beijing-institute-of-biological-products-co-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 27 studies since Apr 22, 2005.

  1. Nov 14, 2016Sinovac Biotech's first study: phase 1 study in ChickenpoxNew to Sinovac BiotechSinovac Biotech · NCT02965404 · 270 enrolled · China
  2. Nov 28, 2016Phase 3 study in ChickenpoxSinovac Biotech · NCT02981836 · 5,997 enrolled · China
  3. Nov 28, 2017GC Biopharma's first study: phase 3 study in Healthy ChildrenNew to GC BiopharmaGC Biopharma · NCT03375502 · 814 enrolled · Korea, Republic of
  4. Feb 14, 2019Phase 3 study in ChickenpoxMerck · NCT03843632 · 150 enrolled · Russian Federation
  5. Oct 14, 2021Phase 4 study in ChickenpoxSinovac Biotech · NCT05095701 · 703 planned · China
  6. Nov 22, 2021Phase 3 study in ChickenpoxSinovac Biotech · NCT05150392 · 1,193 enrolled · China
  7. Jul 12, 20222 phase 4 studies in ChickenpoxSinovac Biotech · NCT05470855, NCT05460429
  8. Dec 20, 2022Sinopharm's first study: phase 3 study in ChickenpoxNew to SinopharmSinopharm · NCT05669625 · 12,440 enrolled · China
  9. Apr 20, 2023Phase 3 study in ChickenpoxSinopharm · NCT05839301 · 1,200 enrolled · China
  10. Mar 6, 2024Phase 3 study in ChickenpoxSinovac Biotech · NCT06314724 · 642 enrolled · Philippines
  11. Jun 26, 2024Phase 4 study in ChickenpoxSinovac Biotech · NCT06484686 · 414 planned · China
  12. Mar 2, 2025Phase 4 study in ChickenpoxSinovac Biotech · NCT06891872 · 720 planned · China
  13. May 15, 20252 phase 4 studiesSinovac Biotech · NCT06987942, NCT06994052
  14. Mar 11, 2026Phase 3 study in ChickenpoxSinovac Biotech · NCT07473427 · 300 planned · Vietnam

Ahead

  1. Dec 2028Primary completion: phase 4 study in ChickenpoxSinovac Biotech · NCT06484686

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 43 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07473427Chickenpox · Vietnam3Not yet recruitingSinovac BiotechAug 1, 2026300
NCT06994052VZV · China4CompletedSinovac BiotechNov 30, 2024412
NCT06987942Chickenpox · China4CompletedSinovac BiotechNov 15, 2024899
NCT06891872Chickenpox · China4Not yet recruitingSinovac BiotechDec 2025720
NCT06484686Chickenpox · China4By invitationSinovac BiotechDec 2028414
NCT06314724Chickenpox · Philippines3CompletedSinovac BiotechSep 6, 2024642
NCT05839301Chickenpox · China3Active, not recruitingSinopharmJul 30, 20231,200
NCT05669625Chickenpox · China3Active, not recruitingSinopharmApr 14, 202412,440
NCT05470855Chickenpox · China4UNKNOWNSinovac BiotechNov 30, 202245,400
NCT05460429Chickenpox · China4UNKNOWNSinovac BiotechMar 15, 202337,920
NCT05150392Chickenpox · China3CompletedSinovac BiotechAug 11, 20181,193
NCT05095701Chickenpox · China4By invitationSinovac BiotechDec 19, 2021703
NCT03843632Chickenpox · Russian Federation3CompletedMerckJun 19, 2020150
NCT03375502Healthy Children · Korea, Republic of3CompletedGC BiopharmaJan 29, 2019814
NCT02981836Chickenpox · China3CompletedSinovac BiotechJun 20175,997
NCT02965404Chickenpox · China1CompletedSinovac BiotechMay 2016270
NCT02519855Herpes Zoster3CompletedMerckJan 26, 2016882
NCT01982409Chickenpox · China4UNKNOWNChangchun Changsheng Life Science and TechnologyJan 2018350
NCT01556451Herpes Zoster4CompletedMerckOct 2012180
NCT01527370Herpes Zoster3CompletedMerckApr 9, 2013250
NCT01505647Herpes Zoster3CompletedMerckJul 2012498
NCT01391546Herpes Zoster3CompletedMerckOct 15, 2012354
NCT01385566Herpes Zoster1CompletedMerckMay 2013223
NCT01245751Herpes Zoster3CompletedMerckJul 2012600
NCT00822237Chickenpox3CompletedMerckOct 2009598
NCT00681031Herpes Zoster4CompletedMerckJun 25, 200896
NCT00624819Streptococcal Infections · Poland3CompletedGlaxoSmithKlineJun 2, 2008524
NCT00568334Chickenpox · Czechia, Hungary2CompletedGlaxoSmithKlineMar 18, 2008244
NCT00561080Prevention of : Herpes-Zoster3CompletedMerckJun 3, 2009759
NCT00550745Herpes Zoster4CompletedMerckJan 200911,999
NCT00546819Herpes Zoster2CompletedMerckAug 2010309
NCT00534248Herpes Zoster3CompletedMerckJan 201022,439
NCT00496327Chickenpox3CompletedMerckOct 6, 2005100
NCT00444860Varicella Virus Infection3CompletedMerckMay 2007150
NCT00432731Chickenpox · France, Italy4CompletedMerckSep 2005500
NCT00432523Measles · France, Germany3CompletedMerckSep 5, 2005752
NCT00406211Rubella · Austria, Germany3CompletedGlaxoSmithKlineDec 2004398
NCT00322231Herpes Zoster3CompletedMerckJul 2007101
NCT00289783Haemophilus Infections · United States, Australia, Mexico3CompletedGlaxoSmithKlineAug 27, 20074,441
NCT00231816Herpes Zoster3CompletedMerckMar 2006763
NCT00226499Chickenpox · Czechia, Greece, Italy and more3CompletedGlaxoSmithKlineOct 12, 20065,803
NCT00197015Hepatitis A · United States3CompletedGlaxoSmithKlineJun 9, 20091,474
NCT00109122Herpes Zoster2CompletedMerckFeb 2003180

How it is read

Names in the registry

  • “Varicella Vaccine”, 4 entries
  • “Investigational live attenuated varicella vaccine”, 4 entries
  • “Zoster Vaccine, Live”, 3 entries
  • “Varicella Virus Vaccine Live”, 2 entries
  • “Live Attenuated Varicella Vaccine”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.